IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

# OVERVIEW OF POLYCYSTIC OVARIAN DISEASE: PATHOPHYSIOLOGY, DIAGNOSIS, AND MANAGEMENT APPROACHES

*Omkar Shinde[1], Pragati Shinde[1], Pooja Shinde[1], Shashikant Sidgur[1], Anjali Shingare[1], and Pallavi Namdas[2]

[1]Students, Sinhgad Institute of Pharmaceutical Sciences, Lonavala, India

[2]Assistant Professor, Sinhgad Institute of Pharmaceutical Sciences, Lonavala, India

**Abstract**

The prevalent endocrine and metabolic condition known as Polycystic Ovarian Disease (PCOD), or Polycystic Ovary Syndrome (PCOS), affects women who are of reproductive age. Due to intricate connections between genetic, hormonal, and environmental variables, it is typified by hyperandrogenism, chronic anovulation, and polycystic ovarian morphology. Its pathogenesis is primarily characterized by insulin resistance and dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis, which lead to metabolic disorders like obesity, dyslipidemia, and hyperinsulinemia. Infertility, hirsutism, irregular menstrual periods, and psychological problems including anxiety and depression are among the symptoms that women come with in clinical settings.

Based on imaging and biochemical analysis, the diagnosis is made using the Rotterdam, NIH, or AE-PCOS criteria. A comprehensive and customized strategy combining pharmaceutical interventions, lifestyle changes, and nutraceutical support is needed for management. While natural substances like myo-inositol, N-acetylcysteine, alpha-lactalbumin, and Ceylon cinnamon show promise in enhancing insulin sensitivity and lowering oxidative stress, insulin-sensitizing medications like metformin continue to be the mainstay of treatment.

In order to enhance long-term metabolic and reproductive results, future developments will prioritize precision medicine, gut microbiota modification, and treatments based on nanotechnology. In order to lower problems and improve the general quality of life for women with PCOD, early diagnosis and multidisciplinary therapy are crucial.

***Keywords***

Polycystic Ovarian Disease (PCOD), Insulin Resistance, Hyperandrogenism, Nutraceutical Therapy, Precision Medicine.

## 1. Introduction:

### 1.1 Background and Definition

Polycystic Ovarian Disease (PCOD), also known as Polycystic Ovary Syndrome (PCOS), is a multifactorial metabolic and endocrine illness that affects women of reproductive age all over the world. Although clinical manifestations vary greatly from patient to patient, it is defined by a combination of polycystic ovarian morphology, chronic anovulation, and hyperandrogenism [1,2]. In addition to being a leading cause of infertility, PCOD is known to have metabolic, cardiovascular, and psychological side effects that have a substantial impact on long-term health and quality of life [3].

The condition was initially identified in 1935 by Stein and Leventhal, who noted a trio of polycystic ovaries, hirsutism, and amenorrhea during a surgical evaluation. As knowledge of PCOD has grown since then, it is now seen as a systemic disorder that affects several organ systems rather than just the ovaries [4]. Early identification and treatment are frequently made more difficult by the clinical variability and overlapping characteristics with other endocrine illnesses.

### 1.2 Epidemiology and Prevalence

In women of reproductive age, the incidence of PCOD varies globally according on study population, ethnicity, and diagnostic criteria, ranging from 8% to 13%; some regional studies show a prevalence as high as 20% [5]. Research shows that compared to Caucasian populations, women of South Asian heritage are especially vulnerable, with greater rates of insulin resistance and metabolic syndrome [6]. The variability of PCOD symptoms is reflected in prevalence estimates that vary by region and rely on whether the NIH, Rotterdam, or AE-PCOS criteria are used [7]. The symptoms of PCOD, which usually appear in adolescence or early adulthood, include obesity, hirsutism, acne, alopecia, and irregular menstrual periods. Over time, untreated metabolic and reproductive issues might result from delayed diagnosis, which is common, especially in moderate phenotypes [8]. Obesity causes clinical symptoms such as insulin resistance, hyperandrogenism, and cardiovascular risk, according to epidemiological research [9].




**Fig.1.2. Worldwide Prevalence of PCOS in Reproductive-Age Women [10]**

### 1.3 Pathophysiology Overview

PCOD has a complex pathophysiology that includes environmental, hormonal, and genetic variables. Dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis, which results in elevated LH secretion in comparison to FSH, lies at the heart of the illness. Anovulation and polycystic ovarian morphology are the results of this imbalance, which also inhibits follicular development and increases the production of androgen by ovarian theca cells [11]. Insulin resistance, which affects between 50 and 70 percent of women with PCOD regardless of weight, is another important factor [12]. Hyperinsulinemia causes metabolic disorders such dyslipidemia and glucose intolerance, increases androgen production, and lowers SHBG levels. A vicious cycle of hormonal and metabolic disturbance is created when insulin resistance and androgen excess are made worse by adipose tissue malfunction and chronic low-grade inflammation [13].

In the pathophysiology of PCOD, oxidative stress and gut microbiome dysbiosis have been implicated in recent studies, indicating possible targets for innovative treatment approaches [14]. With consequences for metabolism, reproduction, and psychology, PCOD is a systemic illness that is highlighted by this growing understanding.




**Fig.1.3. Mechanism of Follicular Development and Premature Ovarian Insufficiency (POI) [15]**

### 1.4 Clinical Significance

PCOD has an impact on several aspects of health. Infertility, irregular menstruation, and an elevated risk of miscarriage are reproductive outcomes, whereas insulin resistance, type 2 diabetes, dyslipidemia, and cardiovascular disease are metabolic outcomes [16]. Furthermore, psychological morbidities like anxiety, depression, and a lower quality of life are common in women with PCOD, which makes management even more difficult [17]. The chronic nature of PCOD, long-term metabolic monitoring, and reproductive therapies result in a significant financial and medical burden. To avoid both short-term reproductive issues and long-term metabolic problems, early detection and thorough treatment are essential.

### 1.5 Rationale for Review

Even with a wealth of studies, PCOD is still underdiagnosed and undertreated, especially in moderate or atypical instances. A thorough, interdisciplinary approach is required because to the diverse clinical presentation, complex pathophysiology, and similarities with other endocrine disorders. Individualized treatment plans are necessary to maximize results, although current management options include lifestyle modifications, pharmaceutical therapy, and nutraceuticals [18]. The goal of this study is to present a comprehensive overview of PCOD, covering its pathophysiology, diagnostic methods, and current management techniques. By combining the most recent research, it draws focus to new therapeutic developments, points out knowledge gaps, and encourages a patient-centered approach.

## 2. Pathophysiology

A complex and multifaceted pathology, PCOD involves interactions between metabolic, endocrine, and genetic processes that impair normal ovarian function. Dysregulation of the hypothalamic-pituitary-ovarian (HPO) axis, which results in an increase in luteinizing hormone (LH) secretion in comparison to follicle-stimulating hormone (FSH), is a key factor in PCOD [19]. Reduced FSH concentration restricts follicular maturation, leading to anovulation and cyst development, whereas elevated LH levels encourage the ovarian theca cells to create excessive amounts of androgens, including testosterone and androstenedione [20].




**Fig.2. Pathophysiology of PCOD [21]**

Insulin resistance, which affects between 50 and 70 percent of women with PCOD regardless of their level of obesity, is another important contributing factor [22]. By working in concert with LH on the theca cells and decreasing the liver's production of sex hormone-binding globulin (SHBG), hyperinsulinemia promotes androgen synthesis and raises the levels of free androgen in the blood [23]. Alopecia, acne, and hirsutism are among the clinical signs brought on by this too androgen environment. Moreover, chronic low-grade inflammation and dysfunctional adipose tissue are important factors in exacerbating hormonal and metabolic abnormalities in PCOD. Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) are pro-inflammatory cytokines released by adipocytes that worsen oxidative stress and disrupt insulin signaling [24]. In turn, oxidative stress encourages follicular arrest and ovarian fibrosis, which prolongs the anovulation cycle [25].

Polymorphisms in genes linked to insulin signaling (INSR), androgen biosynthesis (CYP11A1, CYP17A1), and gonadotropin receptors (LHCGR, FSHR) have been suggested as major genetic variables that contribute to illness vulnerability [26]. Furthermore, in genetically predisposed individuals, environmental factors such a sedentary lifestyle, poor eating habits, and exposure to substances that alter hormones may cause or exacerbate the hormonal imbalance [27]. In conclusion, interrelated metabolic and endocrine disorders lead to PCOD development. The disorder's clinical and metabolic signs are caused by a self-reinforcing cycle that is established by the combined effects of insulin resistance, hyperandrogenism, and HPO axis dysfunction.

### 3. Diagnosis

Polycystic Ovarian Disease (PCOD) is difficult to diagnose because of its diverse character and symptoms that can overlap with those of other endocrine illnesses. Over time, a number of international organizations have put forth diagnostic standards in an effort to standardize diagnosis and enhance clinical results. The criteria developed by the Androgen Excess and PCOS Society (AE-PCOS) in 2006, Rotterdam in 2003, and the National Institutes of Health (NIH) in 1990 are the most commonly utilized [28,29].

The most widely recognized standards in the world are still the Rotterdam criteria (2003), which were developed by agreement between the American Society for Reproductive Medicine (ASRM) and the European Society for Human Reproduction and Embryology (ESHRE). These criteria state that PCOD is diagnosed when two of the three characteristics listed below are present:

1. The anovulation of oligo-
2. Indications of hyperandrogenism that are biological or clinical
3. Ultrasonography of polycystic ovarian morphology (PCOM) [30].

The original official diagnostic guidelines, the NIH 1990 criteria, were more restrictive and did not include all phenotypes because they required both hyperandrogenism and oligo/anovulation [31]. Subsequently, the AE-PCOS Society (2006) highlighted polycystic ovarian morphology or ovarian dysfunction in conjunction with hyperandrogenism as a crucial characteristic [32].

| Criteria | Year | Essential Features | Diagnostic Requirements |
|---|---|---|---|
| **NIH Criteria** | 1990 | Hyperandrogenism and Oligo/Anovulation | Both must be present; excludes PCOM-only cases |
| **Rotterdam Criteria** | 2003 | Oligo/Anovulation, Hyperandrogenism, PCOM | Any two of the three criteria |
| **AE-PCOS Society Criteria** | 2006 | Hyperandrogenism (mandatory), Ovarian dysfunction/PCOM | Hyperandrogenism + either Oligo/Anovulation or PCOM |

**Table 1. Comparison of Major Diagnostic Criteria for PCOD [33]**

Together with these diagnostic standards, biochemical and imaging tests should be part of a thorough review. While transvaginal ultrasonography detects polycystic ovarian morphology, which is defined by ≥12 follicles (2–9 mm in diameter) and/or increased ovarian volume (>10 $cm^3$), serum androgen levels (testosterone, androstenedione, and DHEA-S) aid in the confirmation of hyperandrogenism [34].

To rule out conditions including congenital adrenal hyperplasia, Cushing's syndrome, thyroid dysfunction, and hyperprolactinemia that resemble PCOD symptoms, differential diagnosis is also essential [35]. Effective management of the condition's metabolic, psychological, and reproductive consequences is made possible by early and precise diagnosis.

### 4. Treatment and Management of PCOD

The treatment of polycystic ovarian disease (PCOD) is multifaceted and focuses on the disorder's metabolic, psychosocial, and reproductive components. Treatment for PCOD must be tailored to the patient's primary symptoms, such as hyperandrogenism, irregular menstruation, infertility, or metabolic dysfunction, because the condition's clinical presentations vary widely [36,37].




**Fig.3. Overview of PCOS Etiology and Mechanisms [38]**

### 4.1 Lifestyle Modification

The management of PCOD is based on lifestyle changes because obesity and insulin resistance are key factors in the pathophysiology of the condition. Low-glycemic index carbs, lean protein, and healthy fats are the main components of calorie-controlled diets that dramatically lower hyperinsulinemia and enhance ovulatory function [39]. It has been demonstrated that the Mediterranean diet and the DASH (Dietary Approaches to Stop Hypertension) diet improve hormonal and metabolic profiles [40].

Restoring ovulation, encouraging weight loss, and enhancing insulin sensitivity all depend heavily on physical exercise. Sedentary behavior has been shown to be less effective than regular moderate-intensity exercise (150 minutes per week) or high-intensity interval training (HIIT) in lowering visceral fat and improving insulin resistance markers [41,42].

Behavioral changes including stress reduction, getting enough sleep, and practicing mindfulness also help to maintain hormonal balance and improve adherence to exercise and food plans [43].

### 4.2 Pharmacological Treatment

#### 4.2.1. Role of Insulin-Sensitizing Agents in PCOD

In polycystic ovarian disease (PCOD), insulin resistance (IR) is a key pathophysiological characteristic that contributes to anovulation, hyperandrogenism, and hyperinsulinemia [44]. As a result, increasing insulin sensitivity has emerged as a crucial therapeutic goal for controlling PCOD symptoms and averting metabolic issues. Restoring normal insulin signaling, lowering circulating androgen levels, and enhancing ovulatory function are the goals of insulin-sensitizing drugs [45].




**Fig.4.2.1. Role of Insulin Sensitizing Agents [46]**

The most extensively researched insulin-sensitizing medication for PCOD is metformin, a biguanide. It improves insulin sensitivity by decreasing hepatic gluconeogenesis and increasing peripheral glucose absorption [47]. Metformin lowers serum androgen levels, improves ovulatory frequency, and restores menstrual regularity in women with PCOD, according to clinical research [48]. Additionally, it has been demonstrated that long-term metformin therapy improves lipid profiles and lowers body mass index (BMI), both of which are frequently increased in patients with PCOD [49].

As agonists of the peroxisome proliferator-activated receptor-γ (PPAR-γ), thiazolidinediones (TZDs) like pioglitazone and rosiglitazone enhance the action of insulin in muscle and adipose tissue [50]. Research shows that TZDs lower testosterone levels, restore ovulation, and improve insulin sensitivity [51]. However, its regular usage is restricted due to worries about weight gain and cardiovascular hazards [52].

In addition to pharmacological agents, **nutraceutical insulin sensitizers** like **myo-inositol**, **D-chiro-inositol**, and **N-acetylcysteine (NAC)** have gained attention as safer alternatives. Myo-inositol improves insulin signaling and oocyte quality, leading to improved ovulation rates [53]. NAC, a precursor of glutathione, enhances insulin receptor activity and decreases androgen synthesis, providing both metabolic and antioxidant benefits [54]. Combination therapies involving metformin and inositol or NAC have shown synergistic effects in improving ovulatory and metabolic outcomes in PCOD [55].

Overall, insulin-sensitizing agents address the root metabolic dysfunction in PCOD, improving both reproductive and metabolic parameters. Their role is pivotal in comprehensive management strategies that include lifestyle modification and adjunctive hormonal regulation [56].

### 4.2.2 Insulin-Sensitizing Agents

Because one of the main characteristics of PCOD is insulin resistance, insulin-sensitizing medications are essential for treatment. Metformin, the most often used medication, improves peripheral glucose consumption while decreasing hepatic gluconeogenesis. Along with improving insulin sensitivity, long-term metformin therapy also lowers testosterone levels, improves ovulatory function, and improves menstrual regularity [57]. Metformin also helps stabilize weight and reduces cardiovascular disease and type 2 diabetes risk factors [58].

PPAR-γ receptors are activated by other insulin sensitizers, such as thiazolidinediones like pioglitazone and rosiglitazone, to enhance glucose absorption in adipose tissue. However, these medications are limited by side effects such weight gain, edema, and cardiovascular hazards [59].
Recent research has investigated the possibility of inositols, specifically myo-inositol and D-chiro-inositol, as natural insulin sensitizers that can improve metabolic balance and ovarian function while having less adverse effects than metformin [60].

### 4.2.3 Ovulation Induction

The use of ovulation induction therapy is crucial for women who wish to become pregnant. With better ovulation and live birth rates than clomiphene citrate, letrozole, an aromatase inhibitor, has become the first-line treatment [61]. By preventing the synthesis of estrogen, letrozole increases the secretion of FSH, which stimulates the growth of follicles.

Gonadotropin therapy may be used under close supervision for patients who are resistant to oral ovulation inducers in order to reduce the risk of multiple pregnancies and ovarian hyperstimulation syndrome (OHSS) [62].
Laparoscopic ovarian drilling (LOD), a surgical procedure that eliminates androgen-producing ovarian tissue and lowers LH and androgen levels to restore ovulation, is an option for patients who are not responding to pharmacological therapy [63]. GLP-1 receptor agonists, such as liraglutide, are the focus of more recent pharmacological advancements. These drugs improve weight loss and metabolic regulation and may be useful as an adjuvant in the treatment of PCOD [64].

### 4.3 Nutraceutical and Complementary Approaches

Because they can treat oxidative stress, inflammation, and metabolic dysfunction in PCOD with little adverse effects, nutraceutical therapies are becoming more and more popular.
A glutathione precursor called N-acetylcysteine (NAC) lowers serum testosterone and increases ovulatory frequency while also having antioxidant and insulin-sensitizing properties [65].
Natural insulin signaling mediators myo-inositol and D-chiro-inositol improve lipid metabolism, ovulation cycles, and oocyte quality [66].
By enhancing insulin receptor phosphorylation and decreasing oxidative stress, Ceylon cinnamon (Cinnamomum verum) supplementation enhances glucose homeostasis and monthly regularity [67].
Whey protein component alpha-lactalbumin promotes the bioavailability of tryptophan, aids in the generation of serotonin, and preserves the balance of the gut flora, all of which improve hormonal control and metabolic function [68].
A natural anti-inflammatory and antioxidant, honey reduces systemic inflammation linked to PCOD by regulating oxidative stress and glucose metabolism [69].
When used with conventional pharmaceutical therapy, these nutraceuticals may have synergistic effects that improve treatment efficacy and reduce adverse medication reactions.

### 4.4 Emerging and Future Therapeutic Strategies

It is anticipated that precision medicine will be used in the future to treat PCOD, focusing on each patient's unique genetic, hormonal, and metabolic characteristics [70]. The potential of anti-inflammatory drugs, microbiota-targeted treatments, stem cell therapy, and drug delivery systems based on nanomedicine to increase treatment specificity and reduce adverse effects is still being investigated [71]. A possible path toward safer and more efficient PCOD management is the integration of traditional therapy with nutraceuticals and bioactive substances such NAC, alpha-lactalbumin, cinnamon, and honey [72].

## 5. Conclusion and Future Perspectives

The complex and diverse illness known as polycystic ovarian disease (PCOD) has major effects on metabolism, reproduction, and psychology. It's complicated etiology and diverse spectrum of symptoms continue to present clinicians with challenges, even though it is one of the most prevalent endocrine disorders affecting women of reproductive age. To prevent long-term issues like infertility, type 2 diabetes, obesity, dyslipidemia, and cardiovascular disease, early detection and appropriate treatment are essential [73,74]. A multidisciplinary strategy that includes medication, lifestyle changes, and adjuvant nutraceutical therapies catered to the needs of each patient is necessary for comprehensive management [75].

### 5.1 Future Perspectives in Research and Management

Further investigation into the molecular, genetic, and metabolic causes of PCOD has enormous potential to enhance customized care, diagnosis, and therapy. Polymorphisms in genes related to insulin signaling, steroidogenesis, and gonadotropin control have been found through genetic research, including genome-wide association studies (GWAS), which have shed light on phenotypic variances and vulnerability [76]. By comprehending these molecular processes, precision medicine techniques that customize treatments based on a patient's genetic and metabolic characteristics may become possible.

One possible treatment target for PCOD pathogenesis is the gut microbiota and chronic low-grade inflammation. Prebiotics, probiotics, or dietary changes that alter the gut flora may enhance insulin sensitivity, testosterone levels, and metabolic health in general [77]. Additionally, nutraceuticals including alpha-lactalbumin, myo-inositol, N-acetylcysteine, and Ceylon cinnamon are being researched more and more as complementary therapies to traditional pharmaceutical treatment. Their insulin-sensitizing, anti-inflammatory, and antioxidant qualities may improve ovulatory and metabolic results while lowering negative medication side effects [78,79].

Technological developments in imaging and biomarker identification may also improve PCOD early detection and identify high-risk patients before serious metabolic or reproductive problems arise. Additionally, incorporating digital health technologies—such as smartphone apps for tracking lifestyle, telemedicine consultations, and remote monitoring of metabolic and hormonal parameters—can enable patients to take an active role in managing their conditions, enhancing long-term results and adherence.

### 5.2 Conclusion

In conclusion, PCOD is a multisystem condition that requires early identification, precise diagnosis, and a customized, all-encompassing management strategy. Although lifestyle changes continue to be the mainstay of treatment, pharmaceuticals, together with new nutraceutical and complementary approaches, can greatly enhance metabolic, psychological, and reproductive results. Future studies concentrating on metabolomics, gut microbiome manipulation, genetic profiling, and precision medicine techniques will offer chances to create customized therapies, ultimately enhancing the long-term health and quality of life for women with PCOD.

For best results, a multidisciplinary care approach comprising endocrinologists, gynecologists, nutritionists, mental health specialists, and patient education programs is necessary. The management of PCOD is expected to be redefined by ongoing research into new treatments and the incorporation of cutting-edge technologies, moving away from symptomatic care and toward individualized preventative and restorative therapy that will guarantee long-lasting improvements in metabolic and reproductive health.

**References:**

1. Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S., Legro, R. S., & Lizneva, D. (2016). Polycystic ovary syndrome. *Nature Reviews Disease Primers, 2*(1), 16057.

2. Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., & Pasquali, R. (2014). The polycystic ovary syndrome: A position statement from the European Society of Endocrinology. *European Journal of Endocrinology, 171*(4), P1–P29.

3. Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016). The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis. *Human Reproduction, 31*(12), 2841–2855.

4. Stein, I. F., & Leventhal, M. L. (1935). Amenorrhea associated with bilateral polycystic ovaries. *American Journal of Obstetrics and Gynecology, 29*(2), 181–191.

5. Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). Polycystic ovary syndrome: Etiology, pathogenesis, and diagnosis. *Nature Reviews Endocrinology, 7*(4), 219–231.

6. Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of PCOS. *Endocrine Reviews, 36*(5), 487–525.

7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility and Sterility, 81*(1), 19–25.

8. Palomba, S., Santagni, S., Falbo, A., & La Sala, G. B. (2015). Complications and challenges associated with polycystic ovary syndrome: Current perspectives. *International Journal of Women's Health, 7*, 745–763.

9. Moran, L. J., Hutchison, S. K., Norman, R. J., & Teede, H. J. (2011). Lifestyle changes in women with PCOS. *Cochrane Database of Systematic Reviews, 2*(7), CD007506.

10. Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016). *The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis.* **Human Reproduction, 31**(12), 2841–2855. https://doi.org/10.1093/humrep/dew218

11. Dunaif, A. (2020). Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. *Endocrine Reviews, 41*(4), 465–520.

12. Victor, V. M., Rovira-Llopis, S., Bañuls, C., Diaz-Morales, N., Castelló, R., & Rocha, M. (2016). Insulin resistance in PCOS: Role of oxidative stress and inflammation. *BioMed Research International, 2016*, 1–9.

13. Dokras, A., Clifton, S., Futterweit, W., & Wild, R. (2018). Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: Systematic review and meta-analysis. *Fertility and Sterility, 110*(1), 138–146.

14. Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. E. (2020). Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. *Endocrine Connections, 9*(10), 913–926.

15. Nelson, L. M. (2009). *Primary ovarian insufficiency.* **New England Journal of Medicine, 360**(6), 606–614. https://doi.org/10.1056/NEJMcp0808697

16. Ranasinghe, P., Pigera, S., Premakumara, G. A. S., Galappaththy, P., Constantine, G. R., & Katulanda, P. (2013). Medicinal properties of 'true' cinnamon (Cinnamomum zeylanicum): A systematic review. *BMC Complementary and Alternative Medicine, 13*(1), 275.

17. Cooney, L. G., & Dokras, A. (2017). Depression and anxiety in polycystic ovary syndrome: Etiology and treatment. *Current Psychiatry Reports, 19*(11), 83. https://doi.org/10.1007/s11920-017-0834-2

18. Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., & Norman, R. J. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Human Reproduction, 33*(9), 1602–1618.

19. Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of PCOS. *Endocrine Reviews, 36*(5), 487–525.

20. Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of PCOS. *Endocrine Reviews, 36*(5), 487–525.

21. Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). *Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis.* **Nature Reviews Endocrinology, 7**(4), 219–231. https://doi.org/10.1038/nrendo.2010.217

22. Dunaif, A. (2020). Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. *Endocrine Reviews, 41*(4), 465–520.

23. Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S., Legro, R. S., & Lizneva, D. (2016). Polycystic ovary syndrome. *Nature Reviews Disease Primers, 2*(1), 16057.

24. González, F. (2012). Inflammation in polycystic ovary syndrome: Underpinning of insulin resistance and ovarian dysfunction. *Steroids, 77*(4), 300–305.

25. Victor, V. M., Rovira-Llopis, S., Bañuls, C., Diaz-Morales, N., Castelló, R., & Rocha, M. (2016). Insulin resistance in PCOS: Role of oxidative stress and inflammation. *BioMed Research International, 2016*, 1–9.

26. Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). Polycystic ovary syndrome: Etiology, pathogenesis, and diagnosis. *Nature Reviews Endocrinology, 7*(4), 219–231.

27. Palomba, S., Santagni, S., Falbo, A., & La Sala, G. B. (2015). Complications and challenges associated with polycystic ovary syndrome: Current perspectives. *International Journal of Women's Health, 7*, 745–763.

28. Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., ... & Witchel, S. F. (2006). Position statement: Criteria for defining PCOS as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. *Journal of Clinical Endocrinology & Metabolism, 91*(11), 4237–4245.

29. Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., & Pasquali, R. (2013). Diagnosis and treatment of PCOS: An Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology & Metabolism, 98*(12), 4565–4592.

30. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility and Sterility, 81*(1), 19–25.

31. Zawadzki, J. K., & Dunaif, A. (1992). Diagnostic criteria for polycystic ovary syndrome: Toward a rational approach. In A. Dunaif (Ed.), *Polycystic Ovary Syndrome* (pp. 377–384). Boston: Blackwell Scientific Publications.

32. Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., ... & Witchel, S. F. (2009). The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. *Fertility and Sterility, 91*(2), 456–488.

33. Singh, N., Hooja, N., Yadav, A., & Bairwa, P. (2022). *Comparison of the various diagnostic criteria used in polycystic ovary syndrome. International Journal of Reproduction, Contraception, Obstetrics and Gynecology*, **11**(6), 2198–2202. https://doi.org/10.18203/2320-1770.ijrcog20221933

34. Dewailly, D., Lujan, M. E., Carmina, E., Cedars, M. I., Laven, J., Norman, R. J., & Escobar-Morreale, H. F. (2014). Definition and significance of polycystic ovarian morphology: A task force report from the Androgen Excess and PCOS Society. *Human Reproduction Update, 20*(3), 334–352.

35. Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of PCOS. *Endocrine Reviews, 36*(5), 487–525.

36. Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., & Norman, R. J. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Human Reproduction, 33*(9), 1602–1618.

37. Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., & Pasquali, R. (2013). Diagnosis and treatment of PCOS: An Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology & Metabolism, 98*(12), 4565–4592.

38. Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). *Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis.* Nature Reviews Endocrinology, 7(4), 219–231. https://doi.org/10.1038/nrendo.2010.217

39. Moran, L. J., Hutchison, S. K., Norman, R. J., & Teede, H. J. (2011). Lifestyle changes in women with PCOS. *Cochrane Database of Systematic Reviews, 2*(7), CD007506.

40. Thomson, R. L., Buckley, J. D., & Noakes, M. (2008). The effect of weight loss on PCOS: A systematic review. *Obesity Reviews, 9*(5), 477–491.

41. Hutchison, S. K., Teede, H. J., Rachon, D., & Stepto, N. K. (2011). Exercise improves insulin resistance and reproductive function in PCOS. *Medicine and Science in Sports and Exercise, 43*(6), 972–979.

42. Dunaif, A. (2020). Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. *Endocrine Reviews, 41*(4), 465–520.

43. Bailey, C. J., & Turner, R. C. (1996). Metformin. *New England Journal of Medicine, 334*(9), 574–579.

44. Dunaif, A. (2012). Insulin resistance in women with polycystic ovary syndrome. *Endocrine Reviews, 33*(6), 981–1030. https://doi.org/10.1210/er.2011-1034

45. Diamanti-Kandarakis, E., & Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. *Endocrine Reviews, 33*(6), 981–1030. https://doi.org/10.1210/er.2011-1034

46. Dunaif, A. (1997). *Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis.* Endocrine Reviews, 18(6), 774–800. https://doi.org/10.1210/edrv.18.6.0318

47. Morin-Papunen, L. C., Koivunen, R. M., Ruokonen, A., & Martikainen, H. K. (2012). Metformin improves pregnancy and live-birth rates in women with PCOS. *Human Reproduction, 27*(7), 2146–2153. https://doi.org/10.1093/humrep/des157

48. Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012). Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. *Human Reproduction Update, 18*(5), 618–637. https://doi.org/10.1093/humupd/dms015

49. Morin-Papunen, L., Rautio, K., Ruokonen, A., Hedberg, P., Puukka, M., Tapanainen, J. S., & Martikainen, H. (2016). Long-term metformin therapy in women with polycystic ovary syndrome: Effects

on metabolic and endocrine parameters. *Journal of Clinical Endocrinology & Metabolism, 101*(5), 1943–1951. https://doi.org/10.1210/jc.2015-3413

50. Azziz, R., Ehrmann, D. A., Legro, R. S., Fereshetian, A. G., Ochoa, M., & Dewailly, D. (2009). Thiazolidinediones in the treatment of PCOS: Mechanisms and outcomes. *Fertility and Sterility, 92*(3), 828–835. https://doi.org/10.1016/j.fertnstert.2009.03.040

51. Ghazeeri, G., Kutteh, W. H., & Ke, R. W. (2012). Pioglitazone improves ovulation and metabolic profile in women with polycystic ovary syndrome. *Gynecological Endocrinology, 28*(6), 422–425. https://doi.org/10.3109/09513590.2011.633658

52. Nissen, S. E., & Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *New England Journal of Medicine, 356*(24), 2457–2471. https://doi.org/10.1056/NEJMoa072761

53. Unfer, V., & Nestler, J. E. (2016). Myo-inositol for polycystic ovary syndrome: Insights into a novel therapy. *International Journal of Endocrinology, 2016*, Article 1–9. https://doi.org/10.1155/2016/1946532

54. Fulghesu, A. M., Ciampelli, M., Muzj, G., Belosi, C., Selvaggi, L., Apa, R., & Lanzone, A. (2012). N-acetylcysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. *Fertility and Sterility, 98*(4), 873–878. https://doi.org/10.1016/j.fertnstert.2012.06.026

55. Genazzani, A. D., Prati, A., Santagni, S., Ricchieri, F., Campedelli, A., & Rattighieri, E. (2014). Combined treatment with myo-inositol and metformin in polycystic ovary syndrome. *Gynecological Endocrinology, 30*(5), 365–369. https://doi.org/10.3109/09513590.2014.880478

56. Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., & Norman, R. J. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Human Reproduction, 33*(9), 1602–1618. https://doi.org/10.1093/humrep/dey256

57. Dunaif, A. (2020). Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. *Endocrine Reviews, 41*(4), 465–520. https://doi.org/10.1210/endrev/bnaa005

58. Bailey, C. J., & Turner, R. C. (1996). Metformin. *The New England Journal of Medicine, 334*(9), 574–579. https://doi.org/10.1056/NEJM199602293340906

59. Derosa, G., D'Angelo, A., Romano, D., & Maffioli, P. (2019). Efficacy and safety profile evaluation of pioglitazone and rosiglitazone in patients with diabetes and insulin resistance: A systematic review and meta-analysis. *Diabetes Therapy, 10*(6), 2199–2225. https://doi.org/10.1007/s13300-019-00696-y

60. Facchinetti, F., Bizzarri, M., Benvenga, S., D'Anna, R., Lanzone, A., Soulage, C., Di Renzo, G. C., Hod, M., Cavalli, P., & Bevilacqua, A. (2020). Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology—Assisted reproduction technology. *Gynecological Endocrinology, 36*(10), 1–7. https://doi.org/10.1080/09513590.2020.1774709

61. Legro, R. S., Brzyski, R. G., Diamond, M. P., Coutifaris, C., Schlaff, W. D., Casson, P., Christman, G. M., Huang, H., Hansen, K. R., Baker, V., Haisenleder, D. J., & Santoro, N. (2014). Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. *The New England Journal of Medicine, 371*(2), 119–129. https://doi.org/10.1056/NEJMoa1313517

62. Amer, S. A. (2019). Ovulation induction using gonadotropins in women with polycystic ovary syndrome: Current perspectives. *Reproductive BioMedicine Online, 39*(3), 385–392. https://doi.org/10.1016/j.rbmo.2019.04.008

63. Mitwally, M. F., Abdelrahman, A. A., & Casper, R. F. (2019). Laparoscopic ovarian drilling: Current status and future directions. *Fertility and Sterility, 111*(3), 567–573. https://doi.org/10.1016/j.fertnstert.2019.01.017

64. Elkind-Hirsch, K., Paterson, M. S., Seidemann, E. L., & Gutowski, H. C. (2021). Liraglutide combined with metformin improves weight loss and metabolic control in obese women with PCOS: A randomized trial. *The Journal of Clinical Endocrinology & Metabolism, 106*(3), 1053–1066. https://doi.org/10.1210/clinem/dgaa841

65. Elnashar, A. M. (2018). Role of N-acetylcysteine in the treatment of polycystic ovary syndrome. *Gynecological Endocrinology, 34*(1), 7–12. https://doi.org/10.1080/09513590.2017.1380194

66. Facchinetti, F., et al. (2020). Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology. *Gynecological Endocrinology, 36*(10), 1–7.

67. Ranasinghe, P., Pigera, S., Premakumara, S., Galappaththy, P., Constantine, G. R., & Katulanda, P. (2013). Medicinal properties of "true" cinnamon (Cinnamomum zeylanicum): A systematic review. *BMC Complementary and Alternative Medicine, 13*(1), 275. https://doi.org/10.1186/1472-6882-13-275

68. Gatta, D., Vacca, M., & Bellomo, A. (2021). Alpha-lactalbumin supplementation improves serotonin availability and metabolic function in women with polycystic ovary syndrome. *Nutrients, 13*(4), 1059. https://doi.org/10.3390/nu13041059

69. Erejuwa, O. O., Sulaiman, S. A., & Wahab, M. S. A. (2012). Honey: A novel antioxidant and anti-inflammatory agent for metabolic syndrome management. *Molecules, 17*(4), 4400–4423. https://doi.org/10.3390/molecules17044400

70. Palomba, S., Santagni, S., Falbo, A., & La Sala, G. B. (2023). Novel therapeutic strategies in polycystic ovary syndrome: Toward personalized medicine. *Endocrine Reviews, 44*(3), 295–321. https://doi.org/10.1210/endrev/bnad004

71. Balen, A. H., Morley, L. C., Misso, M., Franks, S., Legro, R. S., Wijeyaratne, C. N., & Norman, R. J. (2021). The management of polycystic ovary syndrome: An update. *Nature Reviews Endocrinology, 17*(11), 682–699. https://doi.org/10.1038/s41574-021-00517-6

72. Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. E. (2022). Inositols and their derivatives in the treatment of polycystic ovary syndrome: A review of randomized controlled trials. *Nutrients, 14*(10), 2108. https://doi.org/10.3390/nu14102108

73. Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., & Norman, R. J. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Human Reproduction, 33*(9), 1602–1618.

74. Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., & Pasquali, R. (2013). Diagnosis and treatment of PCOS: An Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology & Metabolism, 98*(12), 4565–4592.

75. Moran, L. J., Hutchison, S. K., Norman, R. J., & Teede, H. J. (2011). Lifestyle changes in women with PCOS. *Cochrane Database of Systematic Reviews, 2*(7), CD007506.

76. Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). Polycystic ovary syndrome: Etiology, pathogenesis, and diagnosis. *Nature Reviews Endocrinology, 7*(4), 219–231.

77. Torres, P. J., Siakowska, M., Banaszewska, B., Pawelczyk, L., Duleba, A. J., & Kelley, S. T. (2018). Gut microbiota and PCOS: Insights into pathophysiology and emerging therapies. *Trends in Endocrinology & Metabolism, 29*(12), 841–852.

78. Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. E. (2020). Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. *Endocrine Connections, 9*(10), 913–926.

79. Ranasinghe, P., Pigera, S., Premakumara, G. A. S., Galappaththy, P., Constantine, G. R., & Katulanda, P. (2013). Medicinal properties of 'true' cinnamon (Cinnamomum zeylanicum): A systematic review. *BMC Complementary and Alternative Medicine, 13*(1), 275.